SEC Form 4 · accession 0001179110-15-011302
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven D Ertel
Officer — EVP & Chief Operating Officer
Period of report
Jul 15, 2015
Accepted (ET)
Jul 17, 2015 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 15, 2015 | M | 807 | $3.88 | A | 58,463 | D | |
| Common Stock | Jul 15, 2015 | M | 1,193 | $5.28 | A | 59,656 | D | |
| Common Stock | Jul 15, 2015 | S | 2,000 | $31.38 | D | 57,656 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $3.88 | Jul 15, 2015 | M | 807 | D | — | Dec 2, 2020 | Common Stock | 807 | 23,693 | D |
| Option to Purchase Common StockF2 | $5.28 | Jul 15, 2015 | M | 1,193 | D | — | Dec 16, 2021 | Common Stock | 1,193 | 36,307 | D |
Explanation of responses
- F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant.